Bicara Therapeutics Inc. presents three year Phase 1b results for ficerafusp alfa combination in HPV negative HNSCC

Bicara Therapeutics Inc. presents three year Phase 1b results for ficerafusp alfa combination in HPV negative HNSCC
Bicara shows three year HNSCC data

Bicara Therapeutics Inc. released three year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab in first line recurrent or metastatic HPV negative head and neck squamous cell carcinoma (HNSCC).

The Phase 1b dataset, which included approximately 90 patients across three dosing regimens, indicated that deep responses seen in participants were sustained over the long term. The announcement was made during the ASCO26 medical conference and is seen as a significant development in immuno-oncology for this hard-to-treat patient group. Additional data and further analysis may be needed to assess broader clinical implications.

Bicara Therapeutics previously announced ficerafusp alfa as the first EGFR-directed antibody-TGF-beta trap for HPV-negative HNSCC. The company also launched the FORTIFI clinical trial targeting first-line recurrent or metastatic HPV-negative HNSCC patients. Both initiatives reflect Bicara’s focus on addressing unmet medical needs in this patient population.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.